The kit is part of Synthego’s CRISPRevolution family of synthetic guide RNA solutions. It includes a “50 percent money-back guarantee or better editing in any human cell type for research use,” according to a press release.
The kit features four guides from Synthego’s CRISPR Design Tool, provided as high-efficiency chemically modified synthetic sgRNAs, SpCas9 protein and control reagents to optimize transfection protocols.
The kit can be used by all CRISPR researchers, including those developing emerging therapeutic modalities such as CAR-T immunotherapy and treatment of monogenic diseases.
“Synthego’s kits enable us to rapidly modify difficult-to-edit human hematopoietic stem cells, as well as primary T cells, in a cost-effective manner,” said Daniel Dever, PhD, a research instructor in the Porteus Lab at Stanford (Calif.) University.
More articles on data analytics & precision medicine:
UNC researchers find Watson for Genomics tech useful for identifying potential therapies
Former IBM Watson oncologist named VP of precision medicine startup: 4 things to know
Beth Israel Deaconess Medical Center researchers release genomics education guide
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
